Cargando…

Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience()

To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response – novel oral polio vaccine type 2 (nOPV2). The World Health Org...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macklin, Grace R., Peak, Corey, Eisenhawer, Martin, Kurji, Feyrouz, Mach, Ondrej, Konz, John, Gast, Chris, Bachtiar, Novilia Sjafri, Bandyopadhyay, Ananda S., Zipursky, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109087/ https://www.ncbi.nlm.nih.gov/pubmed/35307230 http://dx.doi.org/10.1016/j.vaccine.2022.02.050

Ejemplares similares

Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame
por: Zipursky, Simona, et al.
Publicado: (2017)

Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception
por: Martini Rodrigues, Camila Cristina, et al.
Publicado: (2022)

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
por: Shendale, Stephanie, et al.
Publicado: (2017)

Studies on immune responses and interference of oral polio vaccine (OPV) on seroconversion to rotavirus vaccine
por: Migasena, S., et al.
Publicado: (1992)

The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016
por: Bassey, Bassey Enya, et al.
Publicado: (2018)

Stopping Oral Polio Vaccine (OPV) After Defeating Poliomyelitis in Low- and Middle-Income Countries: Harmful Unintended Consequences? Review of the Nonspecific Effects of OPV
por: Aaby, Peter, et al.
Publicado: (2022)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

The truth about PHEICs
por: Giesecke, Johan
Publicado: (2019)

Preventing Polio Post-eradication: Revertant Proportion Patterns of OPV Serotypes
por: Altamirano, Jonathan, et al.
Publicado: (2017)

Public Health Emergency of International Concern (PHEIC) has Declared Twice in 2014; Polio and Ebola at the Top
por: Soghaier, Mohammed A., et al.
Publicado: (2015)

Determination Factors Associated with Immune Responses Towards First Dose Edmonston-Zagreb (EZ) Measles Vaccine in Indonesian Infants
por: Teni Nurlatifah, HR, et al.
Publicado: (2021)

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame
por: Gaensbauer, James T, et al.
Publicado: (2018)

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
por: Wahid, Rahnuma, et al.
Publicado: (2022)

Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
por: Yeh, Ming Te, et al.
Publicado: (2020)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules
por: Bandyopadhyay, Ananda S., et al.
Publicado: (2017)

OPV Vaccination and Shedding Patterns in Mexican and US Children
por: Altamirano, Jonathan, et al.
Publicado: (2018)

Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines—Lessons Learned From the Global Perspective
por: Ramirez Gonzalez, Alejandro, et al.
Publicado: (2017)

With the COVID-19 PHEIC over, what next?
por: Zarocostas, John
Publicado: (2023)

Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial
por: Kanungo, Suman, et al.
Publicado: (2017)

Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
por: Wahid, Rahnuma, et al.
Publicado: (2021)

Zika virus and microcephaly: why is this situation a PHEIC?
por: Heymann, David L, et al.
Publicado: (2016)

What does it mean to declare monkeypox a PHEIC?
por: Burki, Talha
Publicado: (2022)

Monkeypox PHEIC decision hoped to spur the world to act
por: Zarocostas, John
Publicado: (2022)

Monkeypox as a PHEIC: implications for global health governance
por: Wenham, Clare, et al.
Publicado: (2023)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
por: Sáez-Llorens, Xavier, et al.
Publicado: (2021)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Safeguarding vaccine production and supply strategies for polio eradication endgame
por: Bandyopadhyay, Ananda S., et al.
Publicado: (2021)

Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America
por: Lopez-Medina, Eduardo, et al.
Publicado: (2017)

Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas
por: Pedreira, Cristina, et al.
Publicado: (2017)

Genotype Profiles of Rotavirus Strains in Children under 5-year-old Outpatients with Diarrhea in Bandung, West Java, Indonesia
por: Prasetyo, Dwi, et al.
Publicado: (2022)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Spatial Analyses of Oral Polio Vaccine Transmission in an Community Vaccinated With Inactivated Polio Vaccine
por: Jarvis, Christopher I, et al.
Publicado: (2018)

Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia
por: Nency, Yetty M., et al.
Publicado: (2022)

Monitoring and Validation of the Global Replacement of tOPV with bOPV, April–May 2016
por: Farrell, Margaret, et al.
Publicado: (2017)

Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021
por: Mirzoev, Azamdzhon, et al.
Publicado: (2022)

Between individualism and social solidarity in vaccination policy: the case of the 2013 OPV campaign in Israel
por: Boas, Hagai, et al.
Publicado: (2016)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lmob0qi3vgs8t1g1vv408cvooh